From: TRIM45 aggravates microglia pyroptosis via Atg5/NLRP3 axis in septic encephalopathy
Patient group | |||
---|---|---|---|
Characteristics | All patients | Survivors | Nonsurvivors |
Demographics and underlying conditions | |||
 Number of patients | 47 | 36 | 11 |
 Males, number (%) | 37 (78.7%) | 31 (86.1%) | 6 (54.5%) |
 Age (years) | 73 [60.25,81.75] | 70 [59,79] | 82 [65.5,88.5] |
 Cardiac functional insuffificiency, number (%) | 10 (21.3%) | 8 (22.2%) | 2 (18.1%) |
 Renal functional insuffificiency, number (%) | 14 (27.8%) | 10 (27.8%) | 4 (36.4%) |
 Hypertension, number (%) | 27 (57.4%) | 18 (50%) | 9 (81.8%) |
 Diabetes mellitus, number (%) | 24 (51.1%) | 17 (47.2%) | 7 (63.6%) |
Disease severity, number (%) | |||
 Septic shock | 23 (48.9%) | 14 (38.9%) | 9 (81.8%) |
Baseline parameters | |||
 APACHE II score | 23.11 ± 0.975 | 22.7 ± 1.165 | 24.46 ± 1.686 |
 SOFA score | 8.21 ± 0.515 | 8.23 ± 0.612 | 8.15 ± 0.946 |
Site of infection, number (%) | |||
 Lung | 21 (44.7%) | 14 (38.9%) | 7 (63.6%) |
 Abdomen | 20 (42.6%) | 16 (44.4%) | 4 (36.3%) |
 Urinary tract | 3 (6.4%) | 3 (8.3%) | 0 |
 Other | 3 (6.4%) | 3 (8.3%) | 0 |
Intervention, number (%) | |||
 Mechanical ventilation | 34 (723%) | 23 (63.9%) | 11 (100%) |
 Renal-replacement therapy | 22 (46.8%) | 16 (44.4%) | 6 (54.5%) |
 Length of stay | |||
 In the ICU (days) | 23.5 [12,40.25] | 20 [12, 33] | 38 [16, 55] |